Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Tocilizumab: CAR T-cell therapy in DLBCL

Matthew Frigault • 1 Sep 2020
EBMT 2020
Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies CAR-T Tisagenlecleucel Tocilizumab
ELIANA

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, discusses the use of tocilizumab after CAR T-cell therapy for treatment of cytokine release syndrome (CRS) in refractory diffuse large B-cell lymphoma (DLBCL) patients. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

More from Matthew Frigault

3:05
Real-world efficacy & safety data: CAR-T in DLBCL
Matthew Frigault • 1 Sep 2020

Related Videos

3:19
Safety and efficacy of LV20.19 CAR-T therapy in Richter's transformation and R/R MCL
Nirav Shah • 15 Feb 2023
3:02
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Shah • 15 Feb 2023
2:17
The importance of managing hematologic toxicity associated with CAR-T therapy
Marion Subklewe • 10 Feb 2023
5:36
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy
Veit Buecklein • 9 Dec 2022
The content of VJRegenMed is intended for healthcare professionals